Detalhe da pesquisa
1.
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
Ann Oncol
; 34(12): 1141-1151, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38072514
2.
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
Ann Oncol
; 33(6): 616-627, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35337972
3.
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.
Ann Oncol
; 33(4): 384-394, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35093516
4.
Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
Ann Oncol
; 33(8): 814-823, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35513244
5.
Immunotherapy toxicity: identification and management.
Breast Cancer Res Treat
; 192(1): 1-17, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35015209
6.
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
Ann Oncol
; 32(8): 983-993, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34272041
7.
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
Ann Oncol
; 32(2): 208-217, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33246021
8.
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Ann Oncol
; 32(9): 1148-1156, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34116144
9.
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
Ann Oncol
; 32(12): 1571-1581, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34656740
10.
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
Ann Oncol
; 31(5): 582-589, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32178964
11.
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Ann Oncol
; 31(8): 1001-1010, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32416251
12.
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
Ann Oncol
; 31(11): 1526-1535, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32828825
13.
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.
Ann Oncol
; 31(9): 1223-1230, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32464281
14.
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.
Ann Oncol
; 30(3): 405-411, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30475947
15.
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
Ann Oncol
; 30(3): 397-404, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30475950
16.
A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.
Ann Oncol
; 30(9): 1514-1520, 2019 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31250880
17.
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
Breast Cancer Res Treat
; 174(3): 719-729, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30632023
18.
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
Ann Oncol
; 29(9): 1939-1947, 2018 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30124753
19.
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.
Ann Oncol
; 29(4): 888-894, 2018 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29360932
20.
Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
Ann Oncol
; 33(3): 234-238, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34942341